---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210605"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:42:05.769788+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Palvella Q1 net loss $15.8M; cash $261.9M after $230M equity raise; NDA on track H2 2026

## Summary
- Net loss $15.8M ($1.20/share) vs $8.2M ($0.74) in Q1 2025; R&D spend $9.3M up from $4.1M.
- Cash, cash equivalents & short-term investments $261.9M as of Mar 31, following $230M oversubscribed equity offering in Feb 2026.
- FDA pre-NDA meeting granted for QTORIN rapamycin in microcystic LMs; NDA submission on track for H2 2026.
- Phase 3 SELVA study positive topline results; Phase 2 LOTU initiated; Phase 3 for cutaneous VMs and Phase 2 for DSAP planned H2 2026.
- Appointed Jennifer McDonough (SVP Market Access) and Kent Taylor (SVP Sales) to strengthen pre-launch commercialization team.

## SEC filing metadata
- accession: 0001193125-26-210605
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/0001193125-26-210605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/pvla-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210605
- JSON: https://secwatch.observer/filing/0001193125-26-210605.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210605.txt

## Source-grounded claims
- claim_id: 7918d60aee6bf1549b6d5ab12cf9f2672c09c0fc
  claim: PALVELLA THERAPEUTICS, INC. reported financial results for the first quarter ending March 31, 2026.
  evidence_excerpt: announced its financial results for the quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583648/000119312526210605/0001193125-26-210605-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.